AbSci, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on the stock and has a $8.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on several promising aspects of AbSci’s ABS-101. The upcoming interim results from the Phase 1 trial are anticipated to demonstrate competitive pharmacology and safety, which could significantly boost confidence in AbSci’s design capabilities. If ABS-101 shows a strong safety profile and favorable pharmacokinetics, it could advance directly into more convenient subcutaneous dosing, enhancing its appeal to potential partners.
Moreover, the drug’s pharmacodynamics suggest it could achieve or surpass target engagement levels of existing treatments, and its low immunogenicity profile is another positive factor. The crowded TL1A monotherapy space means differentiation is key, and ABS-101’s unique combination of features could make it attractive to large pharmaceutical companies. Additionally, the potential for a TL1A-bispecific deal by early 2026 further supports the Buy rating, as it could lead to lucrative partnerships before the completion of IND enabling studies.